AR124871A2 - Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes - Google Patents
Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantesInfo
- Publication number
- AR124871A2 AR124871A2 ARP220100291A ARP220100291A AR124871A2 AR 124871 A2 AR124871 A2 AR 124871A2 AR P220100291 A ARP220100291 A AR P220100291A AR P220100291 A ARP220100291 A AR P220100291A AR 124871 A2 AR124871 A2 AR 124871A2
- Authority
- AR
- Argentina
- Prior art keywords
- content
- sialic acid
- galactose
- terminal lysine
- control
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004472 Lysine Substances 0.000 title abstract 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Chemical group CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 229930182830 galactose Chemical group 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 3
- 239000011701 zinc Substances 0.000 abstract 3
- 229910052725 zinc Inorganic materials 0.000 abstract 3
- 239000001963 growth medium Substances 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 229960000598 infliximab Drugs 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
En la presente descripción se proporciona un método para producir un anticuerpo, como un anticuerpo anti-TNFa (por ejemplo, infliximab) que tiene un contenido de lisina C-terminal de aproximadamente 20% a aproximadamente 70%, y un contenido de ácido siálico de aproximadamente 1% a aproximadamente 20%, que comprende el cultivo de una célula que responde al zinc transfectada con ADN que codifica el anticuerpo en el medio de cultivo que comprende al menos 0,5 mM de zinc; y controlar la concentración de zinc en el medio de cultivo, y produce, de este modo, el anticuerpo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791094P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124871A2 true AR124871A2 (es) | 2023-05-17 |
Family
ID=51528780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100976A AR095660A1 (es) | 2013-03-15 | 2014-03-13 | Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
| ARP220100291A AR124871A2 (es) | 2013-03-15 | 2022-02-14 | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100976A AR095660A1 (es) | 2013-03-15 | 2014-03-13 | Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20140273092A1 (es) |
| EP (1) | EP2970980B2 (es) |
| JP (1) | JP2016512029A (es) |
| KR (1) | KR102216003B1 (es) |
| CN (1) | CN105378086B (es) |
| AR (2) | AR095660A1 (es) |
| AU (2) | AU2014237635B2 (es) |
| BR (1) | BR112015022971B1 (es) |
| CA (1) | CA2907140A1 (es) |
| CY (1) | CY1120980T1 (es) |
| DK (1) | DK2970980T3 (es) |
| EA (1) | EA201591807A1 (es) |
| ES (1) | ES2690047T3 (es) |
| HR (1) | HRP20181741T1 (es) |
| IL (1) | IL240689B (es) |
| LT (1) | LT2970980T (es) |
| MX (1) | MX366910B (es) |
| PH (1) | PH12015501837B1 (es) |
| PL (1) | PL2970980T3 (es) |
| PT (1) | PT2970980T (es) |
| RS (1) | RS57791B1 (es) |
| SG (1) | SG11201507577RA (es) |
| SI (1) | SI2970980T1 (es) |
| SM (1) | SMT201800550T1 (es) |
| TW (1) | TWI630216B (es) |
| WO (1) | WO2014149935A1 (es) |
| ZA (1) | ZA201507671B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| JP2016512029A (ja) * | 2013-03-15 | 2016-04-25 | ヤンセン バイオテツク，インコーポレーテツド | 遺伝子組換えタンパク質中のｃ末端リジン、ガラクトース、及びシアル酸含量を制御する製造方法 |
| JP2016527911A (ja) | 2013-08-20 | 2016-09-15 | レック・ファーマシューティカルズ・ディー・ディーＬｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｄ．Ｄ． | ポリペプチドのα−アミド化および／またはＣ末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| CN108350416A (zh) * | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
| BR112018012344A2 (pt) | 2015-12-17 | 2018-12-04 | Janssen Biotech Inc | anticorpos que se ligam especificamente a hla-dr e seus usos |
| WO2017117218A1 (en) | 2015-12-30 | 2017-07-06 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| WO2018031400A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| CA3033661A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7710827B2 (ja) | 2017-06-05 | 2025-07-22 | ヤンセン バイオテツク，インコーポレーテツド | 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質 |
| JP7235733B2 (ja) | 2017-06-05 | 2023-03-08 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｄ－１に特異的に結合する抗体、及び使用方法 |
| WO2019077628A1 (en) * | 2017-10-16 | 2019-04-25 | Council Of Scientific & Industrial Research | ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JOP20200295A1 (ar) | 2018-05-24 | 2020-11-22 | Janssen Biotech Inc | أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| EP3906257A4 (en) * | 2018-12-31 | 2022-09-14 | Momenta Pharmaceuticals, Inc. | USTEKINUMAB PRODUCTION PROCESSES |
| UY38803A (es) | 2019-07-26 | 2021-01-29 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas |
| EP4013783A1 (en) | 2019-08-15 | 2022-06-22 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
| CA3171113A1 (en) | 2020-03-13 | 2021-09-16 | Patrick John DOONAN | Materials and methods for binding siglec-3/cd33 |
| BR112022023978A2 (pt) | 2020-05-27 | 2023-02-07 | Janssen Biotech Inc | Proteínas que compreendem domínios de ligação ao antígeno cd3 e usos dos mesmos |
| US11827708B2 (en) | 2020-07-29 | 2023-11-28 | Janssen Biotech, Inc. | Proteins comprising HLA-G antigen binding domains and their uses |
| UY39467A (es) | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii |
| IL302277A (en) | 2020-10-22 | 2023-06-01 | Janssen Biotech Inc | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| MX2023008909A (es) | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| EP4314055A1 (en) | 2021-03-24 | 2024-02-07 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
| AR125212A1 (es) | 2021-03-24 | 2023-06-28 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas |
| TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| US20250019455A1 (en) | 2021-09-24 | 2025-01-16 | Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
| IL312968A (en) | 2021-11-22 | 2024-07-01 | Janssen Biotech Inc | Compositions comprising enhanced multispecific binding agents for an immune response |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2025032508A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Enpp3 and cd3 binding agents and methods of use thereof |
| US20250136688A1 (en) | 2023-08-07 | 2025-05-01 | Janssen Biotech, Inc. | Stabilized cd3 antigen binding agents and methods of use thereof |
| WO2025137410A1 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
| EP0486526B2 (en) | 1989-08-07 | 2001-03-07 | Peptech Limited | Tumour necrosis factor binding ligands |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| DE69231828T3 (de) * | 1991-03-18 | 2008-06-19 | New York University | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| FR2807767B1 (fr) † | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| CA2450289A1 (en) † | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| US20040185047A1 (en) | 2003-03-21 | 2004-09-23 | Jill Giles-Komar | Anti- TNF antibodies, compositions, methods and uses |
| PL1807504T3 (pl) † | 2004-11-02 | 2011-07-29 | Ares Trading Sa | Bezsurowicza pożywka hodowlana dla komórek ssaczych |
| ES2517603T3 (es) * | 2008-04-07 | 2014-11-03 | Bayer Healthcare, Llc | Procedimientos de producción recombinante de glucoproteínas |
| RU2580020C2 (ru) * | 2011-04-29 | 2016-04-10 | Биокон Рисерч Лимитед | Способ снижения гетерогенности антител и способ получения соответствующих антител |
| EP2729561A4 (en) | 2011-07-08 | 2015-06-24 | Momenta Pharmaceuticals Inc | CELL CULTURE METHOD |
| US9181572B2 (en) * | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| JP2016512029A (ja) * | 2013-03-15 | 2016-04-25 | ヤンセン バイオテツク，インコーポレーテツド | 遺伝子組換えタンパク質中のｃ末端リジン、ガラクトース、及びシアル酸含量を制御する製造方法 |
-
2014
- 2014-03-07 JP JP2016500790A patent/JP2016512029A/ja active Pending
- 2014-03-07 PT PT14768761T patent/PT2970980T/pt unknown
- 2014-03-07 SI SI201430848T patent/SI2970980T1/sl unknown
- 2014-03-07 ES ES14768761.0T patent/ES2690047T3/es active Active
- 2014-03-07 AU AU2014237635A patent/AU2014237635B2/en not_active Ceased
- 2014-03-07 BR BR112015022971-9A patent/BR112015022971B1/pt not_active IP Right Cessation
- 2014-03-07 LT LTEP14768761.0T patent/LT2970980T/lt unknown
- 2014-03-07 MX MX2015012361A patent/MX366910B/es active IP Right Grant
- 2014-03-07 EP EP14768761.0A patent/EP2970980B2/en active Active
- 2014-03-07 SG SG11201507577RA patent/SG11201507577RA/en unknown
- 2014-03-07 HR HRP20181741TT patent/HRP20181741T1/hr unknown
- 2014-03-07 PL PL14768761T patent/PL2970980T3/pl unknown
- 2014-03-07 KR KR1020157029490A patent/KR102216003B1/ko not_active Expired - Fee Related
- 2014-03-07 RS RS20181228A patent/RS57791B1/sr unknown
- 2014-03-07 SM SM20180550T patent/SMT201800550T1/it unknown
- 2014-03-07 EA EA201591807A patent/EA201591807A1/ru unknown
- 2014-03-07 CA CA2907140A patent/CA2907140A1/en active Pending
- 2014-03-07 WO PCT/US2014/021574 patent/WO2014149935A1/en not_active Ceased
- 2014-03-07 CN CN201480015815.5A patent/CN105378086B/zh not_active Expired - Fee Related
- 2014-03-07 DK DK14768761.0T patent/DK2970980T3/en active
- 2014-03-13 US US14/207,915 patent/US20140273092A1/en not_active Abandoned
- 2014-03-13 TW TW103108900A patent/TWI630216B/zh not_active IP Right Cessation
- 2014-03-13 AR ARP140100976A patent/AR095660A1/es not_active Application Discontinuation
-
2015
- 2015-08-20 IL IL240689A patent/IL240689B/en unknown
- 2015-08-20 PH PH12015501837A patent/PH12015501837B1/en unknown
- 2015-10-14 ZA ZA2015/07671A patent/ZA201507671B/en unknown
- 2015-12-23 US US14/757,691 patent/US11149085B2/en not_active Expired - Fee Related
-
2018
- 2018-11-02 CY CY181101150T patent/CY1120980T1/el unknown
-
2020
- 2020-06-11 AU AU2020203864A patent/AU2020203864B2/en not_active Ceased
-
2021
- 2021-09-29 US US17/489,744 patent/US20220089712A1/en not_active Abandoned
-
2022
- 2022-02-14 AR ARP220100291A patent/AR124871A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| HK1257341A1 (zh) | 硷性磷酸酯的制造 | |
| MX384960B (es) | Cultivo celular metabolicamente optimizado | |
| SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
| AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
| MX368656B (es) | Métodos mejorados para la producción de polipéptidos recombinantes. | |
| MY187542A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| AR083354A1 (es) | Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto | |
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| EA201590550A1 (ru) | Композиции и способы получения гликопротеинов | |
| IN2014CN03077A (es) | ||
| AR086200A1 (es) | Hongos filamentosos que tienen un fenotipo de viscosidad alterado | |
| MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
| PH12013502343A1 (en) | Plants having one or more enhanced yield-related traits and method for making the same | |
| WO2012096552A3 (ko) | Ｒｅｘ１을 포함하는 세포 리프로그래밍 조성물 및 이를 이용한 유도 만능줄기세포 제조방법 | |
| MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
| MX2013013063A (es) | Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas. | |
| MX353243B (es) | Metodo para incrementar la secrecion de proteinas recombinantes. | |
| WO2015003811A8 (en) | Methods for producing sialylated therapeutic proteins | |
| MX2017008633A (es) | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. | |
| MX386517B (es) | Produccion de particulas similares a picornavirus en plantas. | |
| AR118125A2 (es) | Péptido, composición, método para identificar células t específicas de péptido fviii, proteína de fusión y método para preparar un péptido fviii | |
| MX2013012163A (es) | Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimiento y metodos para elaborar los mismos. |